CD4 and COVID-19: To explore this hypothesis further, we refined our analysis by investigating the activation status of conventional CD4+ and CD8+ T cells based on their expression level of CD57, a biomarker classically associated with a high cytotoxic potential (i.e., pro-tissue damage) during viral infections and autoimmune disorders, including COVID-19 (37).